Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy

  • Technology appraisal guidance
  • TA307
  • Published: 

Colorectal cancer (metastatic) - aflibercept: appeal announcement

The Institute has received two appeals from: Sanofi and Beating Bowel Cancer.

The appeal received from Beating Bowel Cancer was rejected during the scrutiny phase.

The appeal hearing took place at RIBA, 66 Portland Place, London W1B 1AD on 23 January 2014 at 10am.

The Institute awaits the decision of the Appeal Panel.

This page was last updated: 24 January 2014